DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,016,708 | +0.5% | 24,251 | -2.8% | 0.53% | +6.0% |
| Q2 2023 | $5,985,840 | -5.7% | 24,941 | -1.0% | 0.50% | -7.2% |
| Q1 2023 | $6,349,380 | +1.7% | 25,192 | +7.1% | 0.54% | +0.9% |
| Q4 2022 | $6,243,229 | -1.6% | 23,522 | -4.2% | 0.54% | -9.1% |
| Q3 2022 | $6,342,000 | +1.9% | 24,552 | -0.0% | 0.59% | +8.2% |
| Q2 2022 | $6,226,000 | -10.8% | 24,560 | +3.3% | 0.55% | +4.6% |
| Q1 2022 | $6,977,000 | -7.3% | 23,786 | +4.0% | 0.52% | -0.9% |
| Q4 2021 | $7,525,000 | +6.8% | 22,874 | -1.2% | 0.53% | +2.9% |
| Q3 2021 | $7,048,000 | +17.8% | 23,150 | +3.8% | 0.51% | +18.5% |
| Q2 2021 | $5,982,000 | +22.7% | 22,292 | +3.0% | 0.43% | +17.4% |
| Q1 2021 | $4,874,000 | -0.6% | 21,651 | -1.9% | 0.37% | -5.4% |
| Q4 2020 | $4,904,000 | +1.4% | 22,076 | -1.7% | 0.39% | -2.0% |
| Q3 2020 | $4,834,000 | +18.2% | 22,449 | -2.9% | 0.40% | +17.5% |
| Q2 2020 | $4,090,000 | +24.1% | 23,130 | -2.8% | 0.34% | +17.8% |
| Q1 2020 | $3,295,000 | -11.4% | 23,806 | -1.8% | 0.29% | -14.1% |
| Q4 2019 | $3,720,000 | +29.1% | 24,237 | +21.4% | 0.33% | +17.6% |
| Q3 2019 | $2,882,000 | -0.2% | 19,959 | -1.2% | 0.28% | +1.8% |
| Q2 2019 | $2,888,000 | +7.5% | 20,208 | -0.7% | 0.28% | +6.9% |
| Q1 2019 | $2,686,000 | +50.1% | 20,343 | +17.2% | 0.26% | +30.5% |
| Q4 2018 | $1,790,000 | -5.8% | 17,360 | -0.7% | 0.20% | +7.0% |
| Q3 2018 | $1,900,000 | +7.5% | 17,484 | -2.5% | 0.19% | +16.1% |
| Q2 2018 | $1,768,000 | -5.0% | 17,930 | -5.8% | 0.16% | -3.6% |
| Q1 2018 | $1,862,000 | +123.0% | 19,030 | +111.8% | 0.17% | +98.8% |
| Q4 2017 | $835,000 | +13.9% | 8,987 | +5.2% | 0.08% | +10.5% |
| Q3 2017 | $733,000 | +21.4% | 8,540 | +19.3% | 0.08% | +11.8% |
| Q2 2017 | $604,000 | -1.1% | 7,160 | +0.4% | 0.07% | +1.5% |
| Q1 2017 | $611,000 | +10.7% | 7,134 | +0.7% | 0.07% | +8.1% |
| Q4 2016 | $552,000 | -0.5% | 7,081 | 0.0% | 0.06% | +1.6% |
| Q3 2016 | $555,000 | -23.8% | 7,081 | -1.8% | 0.06% | -24.7% |
| Q2 2016 | $728,000 | +6.4% | 7,211 | 0.0% | 0.08% | +6.6% |
| Q1 2016 | $684,000 | – | 7,211 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |